Varenicline and risk of self-harm: a nested case-control study
Tadrous M, Martins D, Yao Z, Mamdani MM, Juurlink DN, Gomes T, Antoniou T. PLoS One. 2016; 11(9):e0163681.
Publications
The appropriateness and persistence of testosterone replacement therapy in Ontario
Martins D, Yao Z, Tadrous M, Shah BR, Juurlink DN, Mamdani MM, Gomes T; Ontario Drug Policy Research Network. Pharmacoepidemiol Drug Saf. 2017; 26(2):119-26. Epub 2016 Aug 16.
Self-monitoring of blood glucose levels: evaluating the impact of a policy of quantity limits on test-strip use and costs
Gomes T, Martins D, Tadrous M, Paterson JM, Shah BR, Juurlink DN, Singh S, Mamdani MM. Can J Diabetes. 2016; 40(5):431-5. Epub 2016 May 17.
Persistence of antipsychotic treatment in elderly dementia patients: a retrospective, population-based cohort study
Mast G, Fernandes K, Tadrous M, Martins D, Herrmann N, Gomes T. Drugs Real World Outcomes. 2016; 3(2):175-82. Epub 2016 May 13.
Interprovincial variation in antipsychotic and antidepressant prescriptions dispensed in the Canadian pediatric population
Arora N, Knowles S, Gomes T, Mamdani MM, Juurlink DN, Carlisle C, Tadrous M. Can J Psychiatry. 2016; 61(12):758-65. Epub 2016 May 12.
Off-label use of inhaled tobramycin in Ontario, Canada
Tadrous M, Khuu W, Paterson JM, Mamdani MM, Juurlink DN, Gomes T. Thorax. 2016; 71(9):862-4. Epub 2016 May 10.
Variations in costs and use of provincially-funded testosterone replacement therapy across Canada: a population-based study
Tadrous M, Martins D, Lee K, Knowles S, Mamdani MM, Juurlink DN, Gomes T. Expert Rev Pharmacoecon Outcomes Res. 2016; 16(6):803-7.
Performance of the disease risk score in a cohort study with policy-induced selection bias
Tadrous M, Mamdani MM, Juurlink DN, Krahn MD, Levesque LE, Cadarette SM. J Comp Eff Res. 2015; 4(6):607-14. Epub 2015 Nov 3.
Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a 13-year period: a descriptive study
Fraser LA, Albaum JM, Tadrous M, Burden AM, Shariff SZ, Cadarette SM. CMAJ Open. 2015; 3(1):E91-96.
Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access
Burden AM, Tadrous M, Calzavara A, Cadarette SM. Osteoporos Int. 2015; 26(5):1525-33. Epub 2015 Jan 21.